Pharmaceuticals - , ,
Limerick is developing compounds to minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug's desired effects. In the monotherapy setting, the company is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.
Facebook Custom Audiences
Woo Commerce
Apache
Amazon Associates
WordPress.org
Mobile Friendly